Drugs / iNO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03727451 | Jan 2019 → Sep 2021 | pulmonary fibrosis, pulmonary hypertension, pulmonary sarcoidosis | Bellerophon | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03727451 ↗ |
| Route | Inhaled | “inhaled nitric oxide” NCT03727451 ↗ |